What is HMG (Menotropin) 75 IU

HMG (Menotropin) 75 IU is a purified preparation of gonadotropins extracted from the urine of postmenopausal women, studied in research for its ability to stimulate reproductive function. It is intended exclusively for research use.

Regarding its chemical identity, HMG has a molecular formula of Glycoprotein Extract and a molecular weight of ~30,000 g/mol. Its reported canonical sequence is N/A (Complex Glycoprotein Mixture). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include HMG.

Product for research use.

Mechanism of action of HMG

HMG contains equal amounts of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). In females, it stimulates ovarian follicular growth. In males, FSH stimulates Sertoli cells to induce spermatogenesis, while LH stimulates Leydig cells to produce testosterone.

Pharmacokinetics and pharmacodynamics of HMG

Administered intramuscularly or subcutaneously, HMG is slowly absorbed, with a biological half-life that varies significantly (hours to days) depending on the specific glycoprotein composition and the physiological state of the subject.

Scientific evidence on HMG

The available evidence on HMG is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Extensively documented in human clinical medicine for the treatment of infertility. In research models, it is used to investigate gonadal failure, testicular atrophy recovery, and the direct stimulation of endogenous reproductive hormone pathways.

HMG applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

HMG protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for HMG, so no trial schemes or quantities are specified.

The presentations of this product (75 IU) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of HMG

As a general guideline for laboratory handling, lyophilized peptides such as HMG are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 75 IU contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

HMG Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented HMG security profile

The documented safety information in open sources for HMG is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

HMG is a potent hormonal stimulator. In female models, it carries a high risk of Ovarian Hyperstimulation Syndrome (OHSS). In male models, excessive dosing can lead to aromatization of testosterone into estrogen, causing gynecomastia and water retention.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

HMG in a comparative context

Compared to hCG (Human Chorionic Gonadotropin), which only mimics LH, HMG provides both LH and FSH. This makes HMG superior for studying the complete restoration of reproductive function, particularly spermatogenesis, which requires FSH.

History and development of HMG

Menotropins have been used in medicine since the 1960s. They were originally extracted and purified from the urine of menopausal women (who naturally excrete high levels of FSH and LH). Modern recombinant versions exist, but HMG remains a critical research standard.